OncoMatch/Clinical Trials/NCT06558981
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
Is NCT06558981 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for thyroid cancer.
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Prior therapy
Must have received: surgical total or near total thyroidectomy
Surgical total or near total thyroidectomy
Cannot have received: radiation therapy for the head and neck area
Previously received radiation therapy for the head and neck area
Cannot have received: radioiodine (131I)
Previously received 131I treatment
Cannot have received: targeted therapy
Previously received or currently receiving targeted therapy
Cannot have received: immunotherapy
Previously received or currently receiving immunotherapy
Cannot have received: chemotherapy
Previously received or currently receiving chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify